

1 **Signals of significantly increased vaccine breakthrough,**
2 **decreased hospitalization rates, and less severe disease in**
3 **patients with COVID-19 caused by the Omicron variant of**
4 **SARS-CoV-2 in Houston, Texas**

5
6
7 Paul A. Christensen,^{*,†,‡,§} Randall J. Olsen,^{*,†,‡,§} S. Wesley Long,^{*,†,‡,§} Richard Snehal,[†]
8 James J. Davis,^{¶,**} Matthew Ojeda Saavedra,[†] Kristina Reppond,[†] Madison N. Shyer,[†]
9 Jessica Cambric,[†] Ryan Gadd,[†] Rashi M. Thakur,[†] Akanksha Batajoo,[†] Regan
10 Mangham,[†] Sindy Pena,[†] Trina Trinh,[†] Jacob C. Kinskey,[†] Guy Williams,[†] Robert
11 Olson,^{¶,**} Jimmy Gollihar,[‡] James M. Musser^{†,‡,§,††}

12
13 **Contributed equally;*

14 [†]*Laboratory of Human Molecular and Translational Human Infectious Diseases and*

15 [‡]*Laboratory of Antibody Discovery and Accelerated Protein Therapeutics, Center for*

16 *Infectious Diseases, Houston Methodist Research Institute and Department of*

17 *Pathology and Genomic Medicine, Houston Methodist Hospital, Houston, Texas;*

18 [§]*Department of Pathology and Laboratory Medicine, Weill Cornell Medical College, New*

19 *York, New York;*

20 [¶]*Consortium for Advanced Science and Engineering, University of Chicago, Chicago,*

21 *Illinois;*

22 ^{**} *Computing, Environment and Life Sciences, Argonne National Laboratory, Lemont,*
23 *Illinois;*

24

25 ⁺⁺ *Address correspondence to James M. Musser, M.D., Ph.D., Department of Pathology*
26 *and Genomic Medicine, Houston Methodist Research Institute, 6565 Fannin Street,*
27 *Suite B490, Houston, Texas 77030. Tel: 713.441.5890, E-mail:*

28 jmmusser@houstonmethodist.org

29

30 Running head: Omicron variant in Houston, Texas

31

32 Disclosures: None.

33

34 Funding: This project was supported by the Houston Methodist Academic Institute
35 Infectious Diseases Fund; and in part with funds from the National Institute of Allergy
36 and Infectious Diseases, National Institutes of Health, Department of Health and Human
37 Services, under Contract No. 75N93019C00076 (J.J.D.).

38

39 Number of text pages: 13

40 Number of figures: 2

41 Number of tables: 2

42 **Abstract**

43 Genetic variants of SARS-CoV-2 continue to dramatically alter the landscape of the
44 COVID-19 pandemic. The recently described variant of concern designated Omicron
45 (B.1.1.529) has rapidly spread worldwide and is now responsible for the majority of
46 COVID-19 cases in many countries. Because Omicron was recognized very recently,
47 many knowledge gaps exist about its epidemiology, clinical severity, and disease
48 course. A genome sequencing study of SARS-CoV-2 in the Houston Methodist
49 healthcare system identified 4,468 symptomatic patients with infections caused by
50 Omicron from late November 2021 through January 5, 2022. Omicron very rapidly
51 increased in only three weeks to cause 90% of all new COVID-19 cases, and at the end
52 of the study period caused 98% of new cases. Compared to patients infected with either
53 Alpha or Delta variants in our healthcare system, Omicron patients were significantly
54 younger, had significantly increased vaccine breakthrough rates, and were significantly
55 less likely to be hospitalized. Omicron patients required less intense respiratory support
56 and had a shorter length of hospital stay, consistent with on average decreased disease
57 severity. Two patients with Omicron “stealth” sublineage BA.2 also were identified. The
58 data document the unusually rapid spread and increased occurrence of COVID-19
59 caused by the Omicron variant in metropolitan Houston, and address the lack of
60 information about disease character among US patients.

61 [Introduction]

62

63

64 Over the last 14 months, the Alpha and Delta variants of concern (VOCs) of SARS-

65 CoV-2 have caused two distinct COVID-19 disease surges in the United States,

66 Southeast Asia, Europe, and elsewhere ([https://www.cdc.gov/coronavirus/2019-](https://www.cdc.gov/coronavirus/2019-ncov/cases-updates/variant-surveillance/variant-info.html)

67 [ncov/cases-updates/variant-surveillance/variant-info.html](https://www.cdc.gov/coronavirus/2019-ncov/cases-updates/variant-surveillance/variant-info.html)), last accessed December 30,

68 2021; <https://www.gov.uk/government/collections/new-sars-cov-2-variant>, last accessed

69 December 30, 2021), and remodeled the landscape of human behavior and many

70 societies. Delta replaced the Alpha variant as the cause of virtually all COVID-19 in

71 many countries ([https://www.who.int/publications/m/item/weekly-epidemiological-](https://www.who.int/publications/m/item/weekly-epidemiological-update-on-covid-19---13-july-2021)

72 [update-on-covid-19---13-july-2021](https://www.who.int/publications/m/item/weekly-epidemiological-update-on-covid-19---13-july-2021)), last accessed August 18, 2021;

73 <https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditions>

74 [anddiseases/bulletins/coronaviruscovid19infectionsurveyspilot/9july2021](https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditions), last accessed

75 August 18, 2021).

76 At the start of the pandemic almost two years ago, the Houston Methodist

77 healthcare system instituted a comprehensive and integrated population genomics

78 project designed to sequence all SARS-CoV-2 samples causing COVID-19 in patients

79 cared for at our facilities, which include eight hospitals located throughout the

80 metroplex. The project was implemented when the initial Houston Methodist COVID-19

81 case was diagnosed at the end of February 2020, and has continued unabated¹⁻⁷. This

82 project was facilitated by the existence of a single large diagnostic laboratory that

83 serves the entire system and is seamlessly integrated with a research institute with

84 extensive genomics expertise and capacity. A key goal was to comprehensively map

85 the population genomics, trajectory, and other features of the pandemic in metropolitan

86 Houston with a population size of approximately 7.2 million. Houston is the fourth
87 largest city in the United States, the most ethnically diverse metropolitan area in the
88 country, and is a major port of entry. To date, SARS-CoV-2 genomes have been
89 sequenced from greater than 70,000 patient samples. Many features of four distinct
90 SARS-CoV-2 waves in Houston have been described²⁻⁶.

91 The successes of rapid SARS-CoV-2 vaccine development and documented
92 efficacy, coupled with the significant downturn of the disease wave caused by Delta in
93 Houston and elsewhere in fall, 2021⁶, suggested that the pandemic was abating.
94 However, the identification of a new VOC designated B.1.1.529 and known as Omicron
95 that has spread rapidly in South Africa and the UK has tempered this optimism⁸⁻¹⁰.
96 Inasmuch as Omicron was recognized very recently, and much is not known about its
97 epidemiology and clinical characteristics and course, we used our integrated
98 infrastructure in an effort to address the lack of information available for United States
99 Omicron patients. Genome sequencing identified 4,468 COVID-19 patients with
100 symptomatic disease caused by Omicron in the Houston Methodist healthcare system
101 beginning in late November 2021 and ending January 5, 2022. In three weeks Omicron
102 spread throughout the Houston metropolitan region to become the cause of 90% of new
103 COVID-19 cases, and at the end of the study period caused 98% of all new cases.
104 Compared to patients infected with either Alpha or Delta variants and cared for in our
105 system, significantly fewer Omicron patients were hospitalized, and those who were
106 hospitalized required significantly less intense respiratory support and had a shorter
107 length of stay. Our findings are consistent with decreased disease severity among
108 Houston Methodist Omicron patients. Many factors undoubtedly have contributed,

109 including but not limited to increased vaccination uptake, population immunity, and
110 patient demographics such as younger age. The extent to which our findings translate
111 to other cities and other patient populations, including children, is unknown. These data
112 expand on our initial Omicron work⁷ and address the lack of information about disease
113 character among US patients with COVID-19 caused by this VOC.

114

115 **Materials and Methods**

116

117 **Patient Specimens**

118

119 Specimens were obtained from patients registered at Houston Methodist facilities (e.g.,
120 hospitals and urgent care centers), and institutions in the Houston metropolitan region
121 that use our laboratory services. The great majority of individuals had signs or
122 symptoms consistent with COVID-19 disease. For analyses focusing on patients with
123 COVID-19 caused by the Omicron variant, samples obtained from November 27, 2021
124 through January 5, 2022 were used. This time frame was chosen because it represents
125 the period during which an Omicron variant was first identified in our healthcare system
126 and the last date of specimen collection used to generate genome sequence data for
127 this manuscript. Note that the genome data were generated for two distinct sampling
128 periods. The first period included November 27, 2021 through December 23, 2021 and
129 the second period included samples obtained between December 30, 2021 through
130 January 5, 2022. This discontinuous sampling strategy was used in an effort to obtain

131 the most up-to-date data available for inclusion in this study. Because of the substantial
132 number of positive specimens obtained daily in the December 24, 2021 to December
133 29, 2021 period (sometimes exceeding 1,500) it wasn't possible to sequence most of
134 the samples collected during this period for inclusion in the study.

135 For analyses comparing features of patients infected with the Omicron VOC and
136 Alpha and Delta VOCs, all patients documented to be infected with these variants in the
137 Houston Methodist system were studied. The study included 40,991 unique patients
138 identified in this time frame for whom we had SARS-CoV-2 genome sequences. The
139 work was approved by the Houston Methodist Research Institute Institutional Review
140 Board (IRB1010-0199).

141

142 SARS-CoV-2 Molecular Diagnostic Testing

143

144 Specimens obtained from symptomatic patients with a suspicion for COVID-19 disease
145 were tested in the Molecular Diagnostics Laboratory at Houston Methodist Hospital
146 using assays granted Emergency Use Authorization (EUA) from the FDA

147 ([https://www.fda.gov/medical-devices/emergency-situations-medical-devices/faqs-
148 diagnostic-testing-sars-cov-2#offeringtests](https://www.fda.gov/medical-devices/emergency-situations-medical-devices/faqs-diagnostic-testing-sars-cov-2#offeringtests), last accessed June 7, 2021). Multiple

149 molecular testing platforms were used, including the COVID-19 test or RP2.1 test with
150 BioFire Film Array instruments, the Xpert Xpress SARS-CoV-2 test using Cepheid
151 GeneXpert Infinity or Cepheid GeneXpert Xpress IV instruments, the Cobas SARS-
152 CoV-2 & Influenza A/B Assay using the Roche Liat system, the SARS-CoV-2 Assay
153 using the Hologic Panther instrument, the Aptima SARS-CoV-2 Assay using the Hologic

154 Panther Fusion system, the Cobas SARS-CoV-2 test using the Roche 6800 system,
155 and the SARS-CoV-2 assay using Abbott Alinity m instruments. Virtually all tests were
156 performed on material obtained from nasopharyngeal swabs immersed in universal
157 transport media (UTM); oropharyngeal or nasal swabs, bronchoalveolar lavage fluid, or
158 sputum treated with dithiothreitol (DTT) were sometimes used. Standardized specimen
159 collection methods were used (<https://vimeo.com/396996468/2228335d56>, last
160 accessed June 7, 2021).

161

162 SARS-CoV-2 Genome Sequencing, Genome Analysis, and Identification of 163 Variants

164

165 We sequenced the SARS-CoV-2 genome of >90% of all positive cases in the Houston
166 Methodist healthcare system during the two sampling periods studied. Libraries for
167 whole SARS-CoV-2 genome sequencing were prepared according to version 4
168 (<https://community.artic.network/t/sars-cov-2-version-4-scheme-release/312>, last
169 accessed August 19, 2021) of the ARTIC nCoV-2019 sequencing protocol. The semi-
170 automated workflow used has been described previously²⁻⁶. Sequence reads were
171 generated with an Illumina NovaSeq 6000 instrument.

172 Viral genomes were assembled with the BV-BRC SARS-Cov2 assembly service
173 (<https://www.bv-brc.org/app/ComprehensiveSARS2Analysis>, last accessed June 7,
174 2021, requires registration). The pipeline currently uses seqtk version 1.3-r117 for
175 sequence trimming (<https://github.com/lh3/seqtk.git>, last accessed December 30, 2021)
176 and minimap version 2.17 for aligning reads against the Wuhan-Hu-1 (NC_045512.2)

177 reference genome. Samtools version 1.11 was used for sequence and file manipulation,
178 where maximum depth and minimum depth parameters in mpileup were set to 8,000
179 and 3, respectively. iVar version 1.3.1 was used for primer trimming and variant calling.
180 Genetic lineages, VOCs, and variants of interest (VOIs) were identified based on
181 genome sequence data and designated by Pangolin v. 3.1.17 with pangoLEARN
182 module 2021-12-06 (<https://cov-lineages.org/resources/pangolin.html>, last accessed
183 December 12, 2021). Genome data used in this study have been deposited to
184 GISAID www.gisaid.org.

185

186 S-Gene Target-Failure Assay

187

188 An S-gene target-failure (SGTF) assay (TaqPath COVID-19 Combo Kit Thermo Fisher,
189 Inc.), was used as a surrogate marker for the Omicron VOC for some specimens
190 collected between December 18, 2021 and January 5, 2022. From November 1, 2021
191 onward, only Delta and Omicron were documented to be circulating in metropolitan
192 Houston, based on whole-genome sequence data. Patient samples were first tested in
193 the clinical Molecular Diagnostics Laboratory using a RT-PCR assay with an
194 Emergency Use Authorization as described above. The SARS-CoV-2 positive samples
195 were then tested with the SGTF assay according to the manufacturer's instructions to
196 infer an Omicron or not-Omicron lineage. That is, the SGTF assay was only performed
197 on samples known to be positive for SARS-CoV-2. Samples yielding amplification of the
198 S-gene were classified as a Delta variant. The SGTF data were validated based on
199 comparing the results with our extensive genome sequence data.

200

201

202 Patient Metadata and Geospatial Analysis

203

204 Patient metadata were acquired from the electronic medical record by standard

205 informatics methods. Figures showing geospatial distribution of spread for Omicron

206 were generated with Tableau version 2021.2.7 (Tableau Software, LLC, Seattle, WA)

207 using patient home address zip codes. A vaccination breakthrough case was defined as

208 a PCR-positive sample from a patient obtained greater than 14 days after full

209 vaccination (e.g., both doses of the Pfizer or Moderna mRNA vaccines) was completed.

210 A booster vaccination breakthrough case was defined as a PCR-positive sample from a

211 patient obtained greater than 14 days after receiving a third vaccine dose. For some

212 cases, manual chart review was conducted to resolve discrepancies or clarify

213 ambiguities.

214

215

216 Results

217

218 Omicron Epidemiologic Wave

219

220 The first Houston Methodist patient infected with an Omicron variant was identified at

221 the end of November 2021, a time when the Delta VOC was responsible for all COVID-

222 19 cases in metropolitan Houston⁶. During this period, the metropolitan area was
223 experiencing a steady decrease in total number of new COVID-19 cases (**Figure 1**,
224 **Figure 2**).

225 Omicron increased in frequency unusually rapidly over a three-week period in
226 December (**Figure 1**, **Figure 2**). By December 23, the genome sequence data showed
227 that Omicron accounted for >90% of all new COVID-19 cases in our healthcare system
228 (**Figure 2**). The estimated case doubling time during this three-week period was
229 approximately 1.8 days (**Figure 2**), which means that Omicron increased in relative
230 frequency approximately three times faster than Delta had increased in our area⁶, an
231 unprecedented trajectory for SARS-COV-2 infections. By January 5, 2022, the Omicron
232 variant caused 98% of all new COVID-19 cases diagnosed in our healthcare system
233 (**Figure 2**). This represents the fifth wave of COVID-19 cases in metropolitan Houston
234 (**Figure 1**).

235 Consistent with extensive infections caused by Omicron in southern Africa and
236 elsewhere ([https://www.cdc.gov/coronavirus/2019-ncov/variants/variant-](https://www.cdc.gov/coronavirus/2019-ncov/variants/variant-classifications.html)
237 [classifications.html](https://www.cdc.gov/coronavirus/2019-ncov/variants/variant-classifications.html)), last accessed December 28, 2021;
238 <https://www.gov.uk/government/collections/new-sars-cov-2-variant>, last accessed
239 December 28, 2021), several patients had very recent travel histories to countries with a
240 high prevalence of this VOC, suggesting acquisition of virus by some cases from abroad
241 and importation into Houston. However, the vast majority of Omicron patients had no
242 documented travel outside the US and undoubtedly acquired the infection domestically,
243 either in Houston or elsewhere.

244 To understand the geospatial distribution of Omicron in metropolitan Houston,
245 patient metadata were acquired from the electronic medical record by standard
246 informatics methods, and home address zip codes were used to visualize virus spread
247 (**Figure 2**). The 4,468 Houston Methodist patients infected with Omicron during this
248 period were distributed widely throughout metropolitan Houston, with 259 different zip
249 codes represented (**Figure 2**). The widespread distribution of Omicron in the Houston
250 metroplex in an extremely short period of time reflects the ability of this variant to spread
251 unusually rapidly and effectively between individuals, and cause symptomatic disease.

252

253 Comparison of Omicron, Alpha, and Delta COVID-19 Cases

254

255 There is a considerable lack of detailed information about patients with COVID-19
256 caused by the Omicron VOC, and data are especially lacking for US patients. We
257 compared available metadata for all Houston Methodist patients infected with Omicron,
258 Alpha, and Delta VOCs (**Table 1, Table 2**). The populations differed significantly in
259 many characteristics, including median age, hospital admission rates, maximum
260 respiratory support, rate of vaccine breakthrough, and median length of stay (**Table 1,**
261 **Table 2**).

262 Patients infected with Omicron were significantly younger than Alpha and Delta
263 patients (**Table 1, Table 2**). Importantly, Omicron patients were hospitalized significantly
264 less frequently than patients infected with either the Alpha or Delta variants, and had a
265 significantly shorter median hospital length of stay (**Table 1, Table 2**).

266 We next analyzed Omicron vaccine breakthrough cases (**Table 1, Table 2**). We
267 found 2,497 of the 4,468 total Omicron patients (55.9%) for whom we have whole
268 genome sequence data met the CDC definition of vaccine breakthrough cases (**Table 1,**
269 **Table 2**). There was no simple relationship between the time elapsed since
270 administration of the second vaccination dose and the date of vaccination breakthrough.
271 These 2,497 patients received either two doses of the Pfizer-BioNTech BNT162b2 ($n =$
272 1828, 73%) or Moderna mRNA-1273 ($n = 553$, 22%), or one dose of J&J/Janssen JNJ-
273 78436735 ($n = 115$, 5%) vaccine; vaccine type was not specified for one individual. This
274 distribution reflects the majority use of BNT162b2 vaccination doses in our health
275 system. Compared to either Alpha or Delta patients, a significantly greater percentage
276 of patients with breakthrough cases was caused by the Omicron VOC (55.9% compared
277 to 3.2% and 24.3% for Alpha and Delta VOCs, respectively) (**Table 1, Table 2**). We
278 next analyzed individuals with breakthrough cases after receiving a third (booster) dose
279 of either the Pfizer-BioNTech BNT162b2 or Moderna mRNA-1273 vaccine. We found
280 that 711 (15.9%) of the 4,468 Omicron patients met this criteria. Consistent with
281 Omicron causing a significantly increased number of vaccine breakthrough cases, many
282 studies have reported that this variant has reduced sensitivity to antibody neutralization
283 *in vitro*, likely in large part due to the extensive number of amino acid and other
284 structural changes occurring in Omicron spike protein¹¹⁻³⁴.

285

286 Spike-Gene Target-Failure Assay

287

288 To estimate Omicron variant frequency in patient samples not yet sequenced, we
289 performed the TaqPath COVID-19 Combo Kit assay (ThermoFisher) on 1,216 samples
290 collected from symptomatic patients between December 18, 2021 and January 5, 2022
291 In total, 1,093 (90%) of patient samples yielded an RT-PCR result with S-gene target-
292 failure indicative of the Omicron variant. These data are consistent with the increasing
293 frequency of new cases of COVID-19 caused by Omicron in our population (**Figure 2**).

294

295 Discovery of Omicron “Stealth” Sublineage BA.2 in Houston

296

297 The Omicron sublineage BA.2 was first identified in November 2021 in Australia in a
298 patient who had traveled to South Africa ([https://github.com/cov-lineages/pango-](https://github.com/cov-lineages/pango-designation/issues/359)
299 [designation/issues/359](https://github.com/cov-lineages/pango-designation/issues/359); last accessed December 30, 2021). This sublineage does not
300 have the full set of polymorphisms characteristic of BA.1 (B.1.1.529) and also has
301 additional mutations unique to it ([https://github.com/cov-lineages/pango-](https://github.com/cov-lineages/pango-designation/issues/361)
302 [designation/issues/361](https://github.com/cov-lineages/pango-designation/issues/361); last accessed December 30, 2021). One important difference is
303 that sublineage BA.2 lacks the spike gene deletion in the region encoding amino acid
304 69/70 which means that it will not be detected by the SGTF assay. As a consequence, it
305 is sometimes referred to as the Omicron “stealth” variant. We inspected all full genome
306 sequences present in our large database, including specimens obtained from
307 symptomatic patients and asymptomatic individuals, and discovered only two members
308 of the BA.2 sublineage in Houston COVID-19 patients.

309

310 **Discussion**

311

312 This work was conducted to address the relative lack of information about disease
313 character among US patients with COVID-19 caused by the Omicron VOC, and to
314 compare our findings with data available for patients in the Houston Methodist system
315 who had disease caused by the Alpha and Delta VOCs. We describe information
316 relevant to the massive Omicron wave in metropolitan Houston. In three weeks
317 (December 1, 2021 through December 23, 2021), Omicron was first identified in our
318 population and rapidly increased to cause 90% of all new COVID-19 cases, with an
319 unusually fast case doubling time of 1.8 days. Analysis of samples obtained from
320 December 30, 2021 to January 5, 2022 found that at the end of the sampling period
321 Omicron caused 98% of all new COVID-19 cases in our healthcare system.

322 The study was based on genome sequence analysis of 4,468 Omicron samples
323 taken from socioeconomically, geographically, and ethnically diverse symptomatic
324 patients. Several key findings were made, including (i) the Omicron VOC rapidly
325 increased as a cause of COVID-19 and spread throughout the metroplex in an
326 unusually short period of time, far faster than any other SARS-CoV-2 variant; (ii)
327 Omicron caused significantly more vaccine breakthrough cases than the Alpha or Delta
328 VOCs; (iii) Omicron patients were significantly younger than Alpha or Delta patients; (iv)
329 significantly fewer Omicron patients required hospitalization compared to Alpha and
330 Delta patients; (v) the median length of stay for hospitalized Omicron patients was
331 significantly shorter than for Alpha and Delta patients, and consistent with this
332 observation, on average the maximum respiratory support required for Omicron patients

333 was significantly less than for Alpha or Delta patients. Our findings are largely
334 consistent with many aspects of Omicron data reported from the UK, South Africa, and
335 Canada^{8-10, 35-38}, and are consistent with experimental animal infection data suggesting
336 that Omicron causes less severe disease in mice and hamsters³⁹⁻⁴³. This study was
337 facilitated by a comprehensive and integrated population genomics and epidemiology
338 project²⁻⁶ implemented at the end of February 2020, when the initial COVID-19 case
339 was diagnosed in the Houston Methodist healthcare system.

340 Several questions arise from our findings, namely the underlying causes for the
341 differences we observe in Omicron compared to Alpha and Delta patients. We believe
342 the data from the extensive studies examining serologic and structural differences in
343 Omicron relative to Alpha and Delta likely contribute to the increased vaccine
344 breakthrough cases observed. It is also possible that waning of immunity is a
345 contributing factor as well. We do not currently have serologic or other data that could
346 address this possibility in our patients. As noted above, ample *in vitro* and animal
347 infection model data have accumulated suggesting that Omicron is less virulent than
348 Delta or Alpha VOC. We speculate that the lower age of Omicron patients may be
349 attributable to a disproportionately greater likelihood of risky behaviors in the younger
350 population, for example less mask wearing and less social distancing. Regardless,
351 additional studies are required to gain more information about factors contributing to the
352 differences between Alpha, Delta, and Omicron patients that we identified in this study.

353 Because we sequence the genome of approximately 90% of SARS-CoV-2
354 causing COVID-19 in our diverse Houston Methodist patient population, and have done
355 so for almost two years, we are continuously monitoring the composition of this virus in

356 a major US metroplex. This affords us the opportunity to rapidly assess changes in
357 SARS-CoV-2 population genomic structure in the fourth largest city in the US. However,
358 our study has several limitations. Although we sequenced the genomes of SARS-CoV-2
359 causing 90% of all Houston Methodist COVID-19 cases in the study period, this sample
360 represents only approximately 5% of cases reported in the metropolitan region. Our
361 patient population will underrepresent some demographic groups, for example
362 homeless individuals and pediatric patients. The samples sequenced in this study were
363 obtained from symptomatic individuals, which means that it is possible that we failed to
364 identify Omicron subvariants or features preferentially represented in asymptomatic
365 individuals. It is likely that our study included some patients where Omicron was
366 detected on hospital admission but was incidental to the primary cause of admission.

367 The identification of two asymptomatic individuals with the Omicron “stealth”
368 sublineage BA.2 is potentially concerning and stresses the importance of using whole-
369 genome sequencing to study patient samples. This sublineage lacks the spike gene
370 deletion corresponding to amino acids 69 and 70 and is not detected by some
371 commonly used assays. Sublineage BA.2 now accounts for approximately 5% of
372 COVID-19 in the UK, which means that it has the ability to successfully transmit and
373 cause disease⁴⁴. It will be important to determine if this SARS-CoV-2 genotype
374 increases in frequency in metropolitan Houston as additional genome sequencing is
375 conducted on samples from our patient population.

376 In the aggregate, our data add critical new information to features of Omicron
377 genomic epidemiology and patient characteristics in the US. Further, the present study

378 highlights the importance of analyzing SARS-CoV-2 genome data integrated with
379 patient metadata and stresses the need to continue to do this in near-real time as the
380 Omicron surge continues, the virus evolves, and new variants with potentially altered
381 fitness and biomedically relevant phenotypes are generated. Analyses of this type are
382 also important in the context of vaccine formulation and long COVID, an increasing
383 health and economic problem globally. Finally, the strategy we have used in this and
384 previous studies²⁻⁶ are readily applicable to future infectious diseases problems that
385 warrant special attention.

386

387 **Acknowledgments**

388

389 We thank Drs. Marc Boom and Dirk Sostman for their ongoing support, and Dr. Sasha
390 M. Pejerrey for editorial contributions. The research was supported by the Houston
391 Methodist Academic Institute Infectious Diseases Fund and many generous Houston
392 philanthropists. The funders had no role in the design and conduct of the study;
393 collection, management, analysis, and interpretation of the data; preparation, review, or
394 approval of the manuscript; and decision to submit the manuscript for publication.

395

396 We declare that we have no conflict of interest.

397

398 **Author Contributions**

399

400 P.A.C., R.J.O., S.W.L., and J.M.M. had full access to all study data and take
401 responsibility for the integrity of the data and the accuracy of the data analysis; concept
402 and design by J.M.M., P.A.C., R.J.O., and S.W.L; data acquisition, analysis, or
403 interpretation by all authors; drafting of the manuscript by all authors; statistical analysis
404 by P.A.C.; funding obtained by J.M.M. and J.J.D.; and overall supervision by J.M.M.
405 P.A.C., R.J.O., and S.W.L. contributed equally and are co-first authors.

406 **References**

- 407 [1] Dhar MS, Marwal R, Vs R, Ponnusamy K, Jolly B, Bhojar RC, et al.: Genomic
408 characterization and epidemiology of an emerging SARS-CoV-2 variant in Delhi, India.
409 Science 2021, 374:995-999
- 410 [2] Long SW, Olsen RJ, Christensen PA, Bernard DW, Davis JJ, Shukla M, Nguyen M,
411 Saavedra MO, Yerramilli P, Pruitt L, Subedi S, Kuo HC, Hendrickson H, Eskandari G,
412 Nguyen HAT, Long JH, Kumaraswami M, Goike J, Boutz D, Gollihar J, McLellan JS,
413 Chou CW, Javanmardi K, Finkelstein IJ, Musser JM: Molecular Architecture of Early
414 Dissemination and Massive Second Wave of the SARS-CoV-2 Virus in a Major
415 Metropolitan Area. mBio 2020, 11
- 416 [3] Musser JM, Olsen RJ, Christensen PA, Long SW, Subedi S, Davis JJ, Gollihar J:
417 Rapid, widespread, and preferential increase of SARS-CoV-2 B.1.1.7 variant in
418 Houston, TX, revealed by 8,857 genome sequences. medRxiv 2021 [Preprint].
419 doi:2021.2003.2016.21253753
- 420 [4] Olsen RJ, Christensen PA, Long SW, Subedi S, Hodjat P, Olson R, Nguyen M,
421 Davis JJ, Yerramilli P, Saavedra MO, Pruitt L, Reppond K, Shyer MN, Cambric J, Gadd
422 R, Thakur RM, Batajoo A, Finkelstein IJ, Gollihar J, Musser JM: Trajectory of Growth of
423 Severe Acute Respiratory (SARS-CoV-2) Syndrome Coronavirus 2 Variants in Houston,
424 Texas, January through May 2021, Based on 12,476 Genome Sequences. Am J Pathol
425 2021, Oct;191(10):1754-1773
- 426 [5] Long SW, Olsen RJ, Christensen PA, Subedi S, Olson R, Davis JJ, Saavedra MO,
427 Yerramilli P, Pruitt L, Reppond K, Shyer MN, Cambric J, Finkelstein IJ, Gollihar J,
428 Musser JM: Sequence Analysis of 20,453 SARS-CoV-2 Genomes from the Houston

429 Metropolitan Area Identifies the Emergence and Widespread Distribution of Multiple
430 Isolates of All Major Variants of Concern. *Am J Pathol* 2021, Nov 11;S0002-
431 9440(21)00480-6

432 [6] Christensen PA, Olsen RJ, Long SW, Subedi S, Davis JJ, Hodjat P, Walley DR,
433 Kinskey JC, Saavedra MO, Pruitt L, Reppond K, Shyer MN, Cambric J, Gadd R, Thakur
434 RM, Batajoo A, Mangham R, Pena S, Trinh T, Yerramilli P, Nguyen M, Olson R, Snehal
435 R, Gollihar J, Musser JM: Delta Variants of SARS-CoV-2 Cause Significantly Increased
436 Vaccine Breakthrough COVID-19 Cases in Houston, Texas. *Am J Pathol* 2021 Nov
437 11:S0002-9440(21)00480-6

438 [7] Christensen PA, Olsen RJ, Long SW, Snehal R, Davis JJ, Saavedra MO, Reppond
439 K, Shyer MN, Cambric J, Gadd R, Thakur RM, Batajoo A, Mangham R, Pena S, Trinh T,
440 Kinskey JC, Williams G, Olson R, Gollihar J, Musser JM: Early signals of significantly
441 increased vaccine breakthrough, decreased hospitalization rates, and less severe
442 disease in patients with COVID-19 caused by the Omicron variant of SARS-CoV-2 in
443 Houston, Texas. *medRxiv* 2022. [Preprint]. doi:2021.2012.2030.21268560

444 [8] Viana R, Moyo S, Amoako DG, Tegally H, Scheepers C, Lessells RJ, et al.: Rapid
445 epidemic expansion of the SARS-CoV-2 Omicron variant in southern Africa. *medRxiv*
446 2021. [Preprint]. doi:2021.2012.2019.21268028

447 [9] Elliott P, Bodinier B, Eales O, Wang H, Haw D, Elliott J, Whitaker M, Jonnerby J,
448 Tang D, Walters CE, Atchison C, Diggle PJ, Page AJ, Trotter AJ, Ashby D, Barclay W,
449 Taylor G, Ward H, Darzi A, Cooke GS, Chadeau-Hyam M, Donnelly CA: Rapid increase
450 in Omicron infections in England during December 2021: REACT-1 study. *medRxiv*
451 2021. [Preprint]. doi:2021.2012.2022.21268252

- 452 [10] Sheikh AK, Steven; Woolhouse, Mark; McMenamin, Jim; Robertson, Chris. :
453 Severity of Omicron variant of concern and vaccine effectiveness against symptomatic
454 disease: national cohort with nested test negative design study in Scotland. The
455 University of Edinburgh 2021
- 456 [11] Meng B, Ferreira I, Abdullahi A, Kemp SA, Goonawardane N, Papa G, Fatihi S,
457 Charles O, Collier D, Collaboration C-NBC-, Consortium TGtPJ, Choi J, Hyeon Lee J,
458 Mlcochova P, James L, Doffinger R, Thukral L, Sato K, Gupta RK: SARS-CoV-2
459 Omicron spike mediated immune escape, infectivity and cell-cell fusion. bioRxiv 2021.
460 [Preprint]. doi:2021.2012.2017.473248
- 461 [12] Zeng C, Evans JP, Qu P, Faraone J, Zheng Y-M, Carlin C, Bednash JS, Zhou T,
462 Lozanski G, Mallampalli R, Saif LJ, Oltz EM, Mohler P, Xu K, Gumina RJ, Liu S-L:
463 Neutralization and Stability of SARS-CoV-2 Omicron Variant. bioRxiv 2021. [Preprint].
464 doi:2021.2012.2016.472934
- 465 [13] Jacobsen H, Strengert M, Maass H, Ynga Durand MA, Kessel B, Harries M, Rand
466 U, Abassi L, Kim Y, Lueddecke T, Hernandez P, Ortmann J, Heise J-K, Castell S,
467 Gornyk D, Gloeckner S, Melhorn V, Lange B, Dulovic A, Haering J, Junker D,
468 Schneiderhan-Marra N, Poehlmann S, Hoffmann M, Krause G, Cicin-Sain L: Diminished
469 neutralization responses towards SARS-CoV-2 Omicron VoC after mRNA or vector-
470 based COVID-19 vaccinations. medRxiv 2021. [Preprint].
471 doi:2021.2012.2021.21267898
- 472 [14] Eggink D, Andeweg SP, Vennema H, van Maarseveen N, Vermaas K, Vlaemynck
473 B, Schepers R, van Gageldonk-Lafeber AB, van den Hof S, Reusken CBEM, Knol MJ:
474 Increased risk of infection with SARS-CoV-2 Omicron compared to Delta in vaccinated

475 and previously infected individuals, the Netherlands, 22 November to 19 December
476 2021. medRxiv 2021. [Preprint]. doi:2021.2012.2020.21268121

477 [15] Edara V-V, Manning KE, Ellis M, Lai L, Moore KM, Foster SL, Floyd K, Davis-
478 Gardner ME, Mantus G, Nyhoff LE, Bechnack S, Alaaeddine G, Naji A, Samaha H, Lee
479 M, Bristow L, Hussaini L, Ciric CR, Nguyen P-V, Gagne M, Roberts-Torres J, Henry AR,
480 Godbole S, Grakoui A, Sexton M, Piantadosi A, Waggoner JJ, Douek DC, Anderson EJ,
481 Rouphael N, Wrammert J, Suthar MS: mRNA-1273 and BNT162b2 mRNA vaccines
482 have reduced neutralizing activity against the SARS-CoV-2 Omicron variant. bioRxiv
483 2021. [Preprint]. doi:2021.2012.2020.473557

484 [16] Zou j, Xia H, Xie X, Kurhade C, Machado RR, Weaver SC, Ren P, Shi P-Y:
485 Neutralization against Omicron SARS-CoV-2 from previous non-Omicron infection.
486 bioRxiv 2021. [Preprint]. doi:2021.2012.2020.473584

487 [17] Ikemura N, Hoshino A, Higuchi Y, Taminishi S, Inaba T, Matoba S: SARS-CoV-2
488 Omicron variant escapes neutralization by vaccinated and convalescent sera and
489 therapeutic monoclonal antibodies. medRxiv 2021. [Preprint].
490 doi:2021.2012.2013.21267761

491 [18] Dejnirattisai W, Shaw RH, Supasa P, Liu C, Stuart AS, Pollard AJ, Liu X, Lambe T,
492 Crook D, Stuart DI, Mongkolsapaya J, Nguyen-Van-Tam JS, Snape MD, Screaton GR:
493 Reduced neutralisation of SARS-CoV-2 omicron B.1.1.529 variant by post-immunisation
494 serum. Lancet 2021. (in press) doi:10.1016/s0140-6736(21)02844-0

495 [19] Cameroni E, Saliba C, Bowen JE, Rosen LE, Culap K, Pinto D, et al.: Broadly
496 neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift. Nature
497 Research Briefing 2021. [Preprint]. doi:2021.2012.2012.472269

498 [20] Liu L, Iketani S, Guo Y, Chan JF-W, Wang M, Liu L, Luo Y, Chu H, Huang Y, Nair
499 MS, Yu J, Chik KK-H, Yuen TT-T, Yoon C, To KK-W, Chen H, Yin MT, Sobieszczyk ME,
500 Huang Y, Wang HH, Sheng Z, Yuen K-Y, Ho DD: Striking Antibody Evasion Manifested
501 by the Omicron Variant of SARS-CoV-2. Nature Research Briefing 2021. [Preprint].

502 doi:2021.2012.2014.472719

503 [21] Planas D, Saunders N, Maes P, Benhassine FG, Planchais C, Porrot F, Staropoli I,
504 Lemoine F, Pere H, Veyer D, Puech J, Rodary J, Bolland WH, Buchrieser J, Baele G,
505 Dellicour S, Raymenants J, Gorissen S, Geenen C, Vanmechelen B, Wawina T, Marti J,
506 Cuypers L, Seve A, Hocqueloux L, Prazuck T, Lorie ES, REY F, Bruel T, Mouquet H,
507 Andre E, Schwartz O: Considerable escape of SARS-CoV-2 variant Omicron to
508 antibody neutralization. Nature Research Briefing 2021. [Preprint].

509 doi:2021.2012.2014.472630

510 [22] Andrews N, Stowe J, Kirsebom F, Toffa S, Rickeard T, Gallagher E, Gower C, Kall
511 M, Groves N, O'Connell A-M, Simons D, Blomquist PB, Zaidi A, Nash S, Aziz NIBA,
512 Thelwall S, Dabrera G, Myers R, Amirthalingam G, Gharbia S, Barrett JC, Elson R,
513 Ladhani SN, Ferguson N, Zambon M, Campbell CN, Brown K, Hopkins S, Chand M,
514 Ramsay M, Bernal JL: Effectiveness of COVID-19 vaccines against the Omicron
515 (B.1.1.529) variant of concern. medRxiv 2021. [Preprint]. doi:2021.2012.2014.21267615

516 [23] Yu X, Wei D, Xu W, Li Y, Li X, Zhang X, Qu J, Yang Z, Chen E: Reduced sensitivity
517 of SARS-CoV-2 Omicron variant to booster-enhanced neutralization. medRxiv 2021.
518 [Preprint]. doi:2021.2012.2017.21267961

519 [24] Cele S, Jackson L, Khan K, Khoury DS, Moyo-Gwete T, Tegally H, Scheepers C,
520 Amoako D, Karim F, Bernstein M, Lustig G, Archary D, Smith M, Ganga Y, Jule Z,

521 Reedoy K, Cromer D, San JE, Hwa S-H, Giandhari J, Blackburn JM, Gosnell BI, Karim
522 SSA, Hanekom W, NGS-SA, Team C-K, von Gottberg A, Bhiman J, Lessells RJ, Moosa
523 M-YS, Davenport MP, de Oliveira T, Moore PL, Sigal A: SARS-CoV-2 Omicron has
524 extensive but incomplete escape of Pfizer BNT162b2 elicited neutralization and requires
525 ACE2 for infection. medRxiv 2021. [Preprint]. doi:2021.2012.2008.21267417
526 [25] Cao Y, Wang J, Jian F, Xiao T, Song W, Yisimayi A, Huang W, Li Q, Wang P, An
527 R, Wang J, Wang Y, Niu X, Yang S, Liang H, Sun H, Li T, Yu Y, Cui Q, Liu S, Yang X,
528 Du S, Zhang Z, Hao X, Shao F, Jin R, Wang X, Xiao J, Wang Y, Xie XS: B.1.1.529
529 escapes the majority of SARS-CoV-2 neutralizing antibodies of diverse epitopes. Nature
530 Research Briefing 2021. [Preprint]. doi:2021.2012.2007.470392
531 [26] Hansen CH, Schelde AB, Moustsen-Helms IR, Emborg H-D, Krause TG, Moelbak
532 K, Valentiner-Branth P, Institut TIDPGaSS: Vaccine effectiveness against SARS-CoV-2
533 infection with the Omicron or Delta variants following a two-dose or booster BNT162b2
534 or mRNA-1273 vaccination series: A Danish cohort study. medRxiv 2021. [Preprint].
535 doi:2021.2012.2020.21267966
536 [27] Syed AM, Ciling A, Khalid MM, Sreekumar B, Kumar GR, Silva I, Milbes B, Kojima
537 N, Hess V, Shacreaw M, Lopez L, Brobeck M, Turner F, Spraggon L, Taha TY, Tabata
538 T, Chen IP, Ott M, Doudna JA: Omicron mutations enhance infectivity and reduce
539 antibody neutralization of SARS-CoV-2 virus-like particles. medRxiv 2021. [Preprint].
540 doi:2021.2012.2020.21268048
541 [28] Sheward DJ, Kim C, Ehling RA, Pankow A, Castro Dopico X, Martin DP, Reddy ST,
542 Dillner J, Karlsson Hedestam GB, Albert J, Murrell B: Variable loss of antibody potency

543 against SARS-CoV-2 B.1.1.529 (Omicron). bioRxiv 2021. [Preprint].
544 doi:2021.2012.2019.473354

545 [29] Haveri A, Solastie A, Ekström N, Österlund P, Nohynek H, Nieminen T, Palmu AA,
546 Melin M: Neutralizing antibodies to SARS-CoV-2 Omicron variant after 3rd mRNA
547 vaccination in health care workers and elderly subjects and response to a single dose in
548 previously infected adults. medRxiv 2021. [Preprint]. doi:2021.2012.2022.21268273

549 [30] Arien KK, Heyndrickx L, Michiels J, Vereecken K, Van Lent K, Coppens S, Pannus
550 P, Martens GA, Van Esbroeck M, Goossens ME, Marchant A, Bartholomeeusen K,
551 Desombere I: Three doses of the BNT162b2 vaccine confer neutralising antibody
552 capacity against the SARS-CoV-2 B.1.1.529 (Omicron) variant of concern. medRxiv
553 2021. [Preprint]. doi:2021.2012.2023.21268316

554 [31] Willett BJ, Grove J, MacLean O, Wilkie C, Logan N, De Lorenzo G, et al.: The
555 hyper-transmissible SARS-CoV-2 Omicron variant exhibits significant antigenic change,
556 vaccine escape and a switch in cell entry mechanism. medRxiv 2022. [Preprint].
557 doi:2022.2001.2003.21268111

558 [32] Boschi C, Colson P, Bancod A, Moal V, La Scola B: Omicron variant escapes
559 therapeutic mAbs contrary to eight prior main VOC. bioRxiv 2022. [Preprint].
560 doi:2022.2001.2003.474769

561 [33] Dejnirattisai W, Huo J, Zhou D, Zahradník J, Supasa P, Liu C, et al.: Omicron-B.1.1.529
562 leads to widespread escape from neutralizing antibody responses. bioRxiv 2021. [Preprint].
563 doi:10.1101/2021.12.03.471045

564 [34] Banerjee A, Lew J, Kroeker A, Baid K, Aftanas P, Nirmalarajah K, Maguire F,
565 Kozak R, McDonald R, Lang A, Gerdtts V, Straus SE, Gilbert L, Li AX, Mozafarihasjin M,

566 Walmsley S, Gingras A-C, Wrana JL, Mazzulli T, Colwill K, McGeer AJ, Mubareka S,
567 Falzarano D: Immunogenicity of convalescent and vaccinated sera against clinical
568 isolates of ancestral SARS-CoV-2, beta, delta, and omicron variants. bioRxiv 2022.
569 [Preprint]. doi:2022.2001.2013.475409

570 [35] Ulloa AC, Buchan SA, Daneman N, Brown KA: Early estimates of SARS-CoV-2
571 Omicron variant severity based on a matched cohort study, Ontario, Canada. medRxiv
572 2021. [Preprint]. doi:2021.2012.2024.21268382

573 [36] Wolter N, Jassat W, Walaza S, Welch R, Moultrie H, Groome M, Amoako DG,
574 Everatt J, Bhiman JN, Scheepers C, Tebeila N, Chiwandire N, du Plessis M, Govender
575 N, Ismail A, Glass A, Mlisana K, Stevens W, Treurnicht FK, Makatini Z, Hsiao N-y,
576 Parboosing R, Wadula J, Hussey H, Davies M-A, Boule A, von Gottberg A, Cohen C:
577 Early assessment of the clinical severity of the SARS-CoV-2 Omicron variant in South
578 Africa. medRxiv 2021. [Preprint]. doi:2021.2012.2021.21268116

579 [37] SARS-CoV-2 variants of concern and variants under investigation in England
580 Technical briefing: Update on hospitalisation and vaccine effectiveness for Omicron
581 VOC-21NOV-01 (B.1.1.529) UK Health Security: UK Health Security, 2021.

582 [38] Davies M-A, Kassanje R, Rousseau P, Morden E, Johnson L, Solomon W, et al.:
583 Outcomes of laboratory-confirmed SARS-CoV-2 infection in the Omicron-driven fourth
584 wave compared with previous waves in the Western Cape Province, South Africa.
585 medRxiv 2022. [Preprint]. doi:2022.2001.2012.22269148

586 [39] Bentley EG, Kirby A, Sharma P, Kipar A, Mega DF, Bramwell C, Penrice-Randal R,
587 Prince T, Brown JC, Zhou J, Screatton GR, Barclay WS, Owen A, Hiscox JA, Stewart
588 JP: SARS-CoV-2 Omicron-B.1.1.529 Variant leads to less severe disease than Pango B

589 and Delta variants strains in a mouse model of severe COVID-19. bioRxiv 2021.
590 [Preprint]. doi:2021.2012.2026.474085


591 [40] Abdelnabi R, Foo CS, Zhang X, Lemmens V, Maes P, Slechten B, Raymenants J,
592 André E, Weynand B, Dallemier K, Neyts J: The omicron (B.1.1.529) SARS-CoV-2
593 variant of concern does not readily infect Syrian hamsters. bioRxiv 2021. [Preprint].
594 doi:2021.2012.2024.474086

595 [41] Diamond M, Peter H, Tadashi M, Kiyoko I-H, Shun I, Maki K, et al.: The SARS-
596 CoV-2 B.1.1.529 Omicron virus causes attenuated infection and disease in mice and
597 hamsters Nature Portfolio 2022. 29 December 2021. [Preprint].
598 doi:<https://doi.org/10.21203/rs.3.rs-1211792/v1>


599 [42] McMahan K, Giffin V, Tostanoski L, Chung B, Siamatu M, Suthar M, Halfmann P,
600 Kawaoka Y, Piedra-Mora C, Martinot A, Kar S, Andersen H, Lewis MG, Barouch DH:
601 Reduced Pathogenicity of the SARS-CoV-2 Omicron Variant in Hamsters. bioRxiv 2022.
602 [Preprint]. doi:2022.2001.2002.474743

603 [43] Yuan S, Ye Z-W, Liang R, Tang K, Zhang AJ, Lu G, Ong CP, Poon VK-M, Chan
604 CC-S, Mok BWY, Qin Z, Xie Y, Sun H, Tsang JO-L, Yuen TT-T, Chik KK-H, Chan CC-
605 Y, Cai J-P, Luo C, Lu L, Yip CC-Y, Chu H, To KK-W, Chen H, Jin D-Y, Yuen K-Y, Chan
606 JFW: The SARS-CoV-2 Omicron (B.1.1.529) variant exhibits altered pathogenicity,
607 transmissibility, and fitness in the golden Syrian hamster model. bioRxiv 2022.
608 [Preprint]. doi:2022.2001.2012.476031

609 [44] SARS-CoV-2 variants of concern and variants under investigation in England
610 Technical briefing 34. UK Health Security Agency. January 14, 2022.
611



612
613 **Figure 1** Epidemiologic curve showing five COVID-19 disease waves in Houston
614 Methodist patients. Number of new COVID-19 cases (y-axis) totals are shown as a +/-
615 three-day moving average. Each of the five waves is shown in a different color. The first
616 and second waves were composed of a heterogenous array of SARS-CoV-2 genotypes.
617 The Alpha VOC shown in the third wave, the Delta VOC shown in the fourth, and the
618 Omicron VOC shown in the fifth wave indicate their numeric prominence in those
619 waves. The figure should not be interpreted to mean that all cases in the third,
620 and fifth waves were caused by Alpha, Delta, and Omicron VOCs, respectively. Rather,
621 they are the dominant single VOCs causing disease in Houston Methodist system
622 patients in those waves. The fifth wave shown includes data through January 5, 2022.
623 The figure was generated with Tableau version 2021.2.7 (Tableau Software, LLC,
624 Seattle, WA), and is a modified version of one presented recently⁶. The curve is
625 essentially superimposable on COVID-19 activity in all metropolitan Houston, Texas.



626

627 **Figure 2** Increase in Omicron frequency over time and distribution in metropolitan
628 Houston. The study time frame was November 27, 2021 through January 5, 2022. **A:**
629 Omicron logistic growth model. The estimated case doubling time is 1.8 days. **B:**
630 Cumulative increase in Omicron during the study period; y-axis is the cumulative
631 number of new COVID-19 Omicron cases. At the end of the study period, Omicron
632 caused 98% of all COVID-19 cases. The plateau between December 24, 2021 and
633 December 30, 2021 exists because we did not sequence samples obtained during this
634 period due to the massive number of daily positive specimens, as described in the
635 Materials and Methods section. **C – F:** Geospatial distribution of Omicron based on
636 home address zip code for each patient. **C:** November 27 – December 6; **D:** November
637 27 – December 16; **E:** November 27 – December 26; **F:** November 27 – January 5.
638 Note differences in heat map scale for each panel. Figures were generated using
639 Tableau version 2021.2.7. (Tableau Software, LLC, Seattle, WA).

640 **Table 1. Summary of pertinent patient metadata for 7,617 unique patients infected**
 641 **with Omicron or Alpha variants.**

	Omicron Variant	Alpha Variant	Total	Statistical Analysis
No. (%) with data	4468 (58.7%)	3149 (41.3%)	7617	
Patient Characteristics				
Median Age (Years)	44.3	50.0	47.2	$P < 0.0001$ Mann-Whitney
Female	2584 (57.8%)	1617 (51.3%)	4201 (55.2%)	$P < 0.0001$ Fisher's exact test
Male	1884 (42.2%)	1532 (48.7%)	3416 (44.8%)	
Ethnicity				
Caucasian	1627 (36.4%)	1240 (39.4%)	2867 (37.6%)	$P < 0.0001$ Chi-square
Hispanic or Latino	992 (22.2%)	942 (29.9%)	1934 (25.4%)	
Black	1376 (30.8%)	729 (23.2%)	2105 (27.6%)	
Asian	203 (4.5%)	122 (3.9%)	325 (4.3%)	
Other	29 (0.6%)	32 (1.0%)	61 (0.8%)	
Unavailable	241 (5.4%)	84 (2.7%)	325 (4.3%)	
BMI				
Median BMI	29.0	30.5	29.6	$P < 0.0001$ Mann-Whitney
Admission Data				
Admitted	884 (19.8%)	1719 (54.6%)	2603 (34.2%)	$P < 0.0001$ Fisher's exact test Odds Ratio: 0.205 (95% CI 0.185- 0.227)
Not Admitted	3584 (80.2%)	1430 (45.4%)	5014 (65.8%)	
Median LOS (Days) (Discharged patients only)	3.2	5.1	4.7	$P < 0.0001$ Mann-Whitney
Max Respiratory Support				
ECMO	1 (0.1%)	7 (0.4%)	8 (0.3%)	$P < 0.0001$ Chi-square
Mechanical Ventilation	49 (5.5%)	144 (8.4%)	193 (7.4%)	

Non-Invasive Ventilation	63 (7.1%)	163 (9.5%)	226 (8.7%)	
High Flow Oxygen	72 (8.1%)	364 (21.2%)	436 (16.7%)	
Low Flow Oxygen	314 (35.5%)	722 (42.0%)	1036 (39.8%)	
Room Air	385 (43.6%)	319 (18.6%)	704 (27.0%)	
Mortality				
Alive	4430 (99.1%)	2979 (94.6%)	7409 (97.3%)	$P < 0.0001$
Deceased	38 (0.9%)	170 (5.4%)	208 (2.7%)	Fisher's exact test
				Odds Ratio: 0.150 (95% CI 0.105- 0.214)
Median PCR Cycle Threshold				
Abbott Alinity	20.8 n=1961	22.4 n=1049	n=3010	$P = 0.0001$ Mann-Whitney
Hologic Panther	22.7 n=476	24.2 n=355	n=831	$P = 0.0745$ Mann-Whitney
Vaccine				
Not Fully Vaccinated	1971 (44.1%)	3048 (96.8%)	5019 (65.9%)	$P < 0.0001$
Fully Vaccinated	2497 (55.9%)	101 (3.2%)	2598 (34.1%)	Fisher's exact test
				Odds Ratio: 38.232 (95% CI 31.088- 47.017)

642 BMI: body mass index; CI: confidence interval; ECMO: extracorporeal membrane oxygenation; LOS: length of stay

643 **Table 2. Summary of pertinent patient metadata for 20,196 unique patients**
 644 **infected with Omicron or Delta variants.**

	Omicron Variant	Delta Variant	Total	Statistical Analysis
No. (%) with data	4468 (22.1%)	15728 (77.9%)	20196	
Patient Characteristics				
Median Age (Years)	44.3	48.3	47.6	$P < 0.0001$ Mann-Whitney
Female	2584 (57.8%)	8123 (51.6%)	10707 (53.0%)	$P < 0.0001$ Fisher's exact test
Male	1884 (42.2%)	7605 (48.4%)	9489 (47.0%)	
Ethnicity				
Caucasian	1627 (36.4%)	6903 (43.9%)	8530 (42.2%)	$P < 0.0001$ Chi-square
Hispanic or Latino	992 (22.2%)	4179 (26.6%)	5171 (25.6%)	
Black	1376 (30.8%)	3450 (21.9%)	4826 (23.9%)	
Asian	203 (4.5%)	531 (3.4%)	734 (3.6%)	
Other	29 (0.6%)	112 (0.7%)	141 (0.7%)	
Unavailable	241 (5.4%)	553 (3.5%)	794 (3.9%)	
BMI				
Median BMI	29.0	29.6	29.4	$P < 0.0001$ Mann-Whitney
Admission Data				
Admitted	884 (19.8%)	6779 (43.1%)	7663 (37.9%)	$P < 0.0001$ Fisher's exact test Odds Ratio: 0.326 (95% CI 0.301- 0.353)
Not Admitted	3584 (80.2%)	8949 (56.9%)	12533 (62.1%)	
Median LOS (Days) (Discharged patients only)	3.2	5.4	5.2	$P < 0.0001$ Mann-Whitney
Max Respiratory Support				
ECMO	1 (0.1%)	19 (0.3%)	20 (0.3%)	$P < 0.0001$ Chi-square
Mechanical Ventilation	49 (5.5%)	727 (10.7%)	776 (10.1%)	

Non-Invasive Ventilation	63 (7.1%)	641 (9.5%)	704 (9.2%)	
High Flow Oxygen	72 (8.1%)	1796 (26.5%)	1868 (24.4%)	
Low Flow Oxygen	314 (35.5%)	2290 (33.8%)	2604 (34.0%)	
Room Air	385 (43.6%)	1306 (19.3%)	1691 (22.1%)	
Mortality				
Alive	4430 (99.1%)	14889 (94.7%)	19319 (95.7%)	$P < 0.0001$
Deceased	38 (0.9%)	839 (5.3%)	877 (4.3%)	Fisher's exact test Odds Ratio: 0.152 (95% CI 0.110-0.211)
Median PCR Cycle Threshold				
Abbott Alinity	20.8 n=1961	21.5 n=5122	n=7083	$P < 0.0001$ Mann-Whitney
Hologic Panther	22.7 n=476	22.6 n=1298	n=1774	$P = 0.1606$ Mann-Whitney
Vaccine				
No vaccine	1815 (40.6%)	11415 (72.6%)	13230 (65.5%)	$P < 0.0001$
>7 days past 1st Vaccine	156 (3.5%)	494 (3.1%)	650 (3.2%)	Chi-square
>14 days past 2nd Vaccine	1786 (40.0%)	3679 (23.4%)	5465 (27.1%)	
>14 days past 3rd Vaccine	711 (15.9%)	140 (0.9%)	851 (4.2%)	

645 BMI: body mass index; CI: confidence interval; ECMO: extracorporeal membrane oxygenation; LOS: length of stay